SCHEMBL19083881

SCHEMBL19083881

CC1(F)CCN(Cc2ccc(C(F)(F)F)cc2Cl)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.47
OPRL1 P41146 4/20 0.44
OPRM1 P35372 1/20 0.44
P2RX7 Q99572 1/20 0.41
CYP2A13 Q16696 1/20 0.40
DRD2 P14416 1/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
POLB P06746 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
C5AR1 P21730 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
ACHE P22303 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MAOA P21397 1/20 0.38
GAA P10253 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19083727 0.89 OPRL1 (0.46) FAAHOPRL1OPRM1DRD2KDM4E
SCHEMBL21075502 0.86 POLB (0.49) OPRL1DRD2KDM4EALDH1A1POLB
SCHEMBL19075631 0.86 FAAH (0.45) FAAHOPRL1OPRM1P2RX7CYP2A13
SCHEMBL19083688 0.83 SCN9A (0.47) FAAHOPRL1OPRM1ALDH1A1
SCHEMBL20697775 0.77 OPRL1 (0.46) FAAHOPRL1OPRM1DRD2KDM4E
SCHEMBL19083729 0.75 OPRL1 (0.46) OPRL1OPRM1KDM4EALDH1A1POLB
SCHEMBL21075641 0.74 CYP2D6 (0.40) OPRL1DRD2ALDH1A1POLB
SCHEMBL19083685 0.74 CYP2D6 (0.52) FAAHOPRL1OPRM1ALDH1A1MEN1
SCHEMBL12665737 0.72 KCNH2 (0.59) OPRL1OPRM1DRD2KDM4EALDH1A1
SCHEMBL19427314 0.71 SCN9A (0.50) FAAHOPRL1OPRM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3166939-B1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2019-06-05 EP disclosed
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190662-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF RDX, C1R, MTX1 FAAH 3152/4885OPRL1 666/4885OPRM1 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.